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Abstract
Background: Estonia has experienced an HIV epidemic among intravenous drug users (IDUs) with the highest per
capita HIV prevalence in Eastern Europe. We assessed the effects of expanded syringe exchange programs (SEP) in
the capital city, Tallinn, which has an estimated 10,000 IDUs.
Methods: SEP implementation was monitored with data from the Estonian National Institute for Health
Development. Respondent driven sampling (RDS) interview surveys with HIV testing were conducted in Tallinn in
2005, 2007 and 2009 (involving 350, 350 and 327 IDUs respectively). HIV incidence among new injectors (those
injecting for < = 3 years) was estimated by assuming (1) new injectors were HIV seronegative when they began
injecting, and (2) HIV infection occurred at the midpoint between first injection and time of interview.
Results: SEP increased from 230,000 syringes exchanged in 2005 to 440,000 in 2007 and 770,000 in 2009. In all
three surveys, IDUs were predominantly male (80%), ethnic Russians (>80%), and young adults (mean ages 24 to
27 years). The proportion of new injectors decreased significantly over the years (from 21% in 2005 to 12% in 2009,
p = 0.005). HIV prevalence among all respondents stabilized at slightly over 50% (54% in 2005, 55% in 2007, 51% in
2009), and decreased among new injectors (34% in 2005, 16% in 2009, p = 0.046). Estimated HIV incidence among
new injectors decreased significantly from 18/100 person-years in 2005 and 21/100 person-years in 2007 to 9/100
person-years in 2009 (p = 0.026).
Conclusions: In Estonia, a transitional country, a decrease in the HIV prevalence among new injectors and in the
numbers of people initiating injection drug use coincided with implementation of large-scale SEPs. Further
reductions in HIV transmission among IDUs are still required. Provision of 70 or more syringes per IDU per year
may be needed before significant reductions in HIV incidence occur.
Background
The estimated number of adults and children living with
HIV in Eastern Europe and Central Asia rose to 1.5 million
in 2008, a 66% increase from 0.9 million in 2001. Three
countries in the region (Estonia, Russian Federation and
Ukraine) have adult (15-49) HIV prevalence that exceeds
1% [1]. Injecting drug use remains the primary mode of
HIV transmission in the region [1,2]. Although coverage
with HIV prevention, treatment and care services (syringe
exchange programs (SEPs), opioid substitution therapy
(OST) and antiretroviral therapy (ART)) for injecting drug
users (IDUs) remains low in the region, scattered progress
has been reported in expanding SEP and OST programs
[3]. Availability of SEP, OST programs and ART and gov-
ernment policies supporting these programs varies widely
across the regions. It is estimated that in Eastern Europe
an average of 9 needles/syringes are distributed by injection
drug user (IDU) per year (ranging from 4 in Russia to 151
in Czech Republic), 1% of IDUs receive OST (ranging from
1% in Georgia and Belarus to 20% in Hungary), and 1%
of HIV infected IDUs receive ART (ranging from <1% in
Russia to 81% in Czech Republic) [3].
There is considerable evidence that HIV-prevention
programs for IDUs, particularly combined programming,
in which multiple programs are provided, can be effective
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any medium, provided the original work is properly cited.in reducing injection-related HIV transmission [4,5]. In
many areas in industrialized countries, it has been possi-
ble to keep prevalence low indefinitely, literally prevent-
ing HIV epidemics among IDUs [6-9]. It is also possible
to “reverse” large-scale HIV epidemics among IDUs (i.e.
to greatly reduce both HIV incidence and prevalence)
with large scale prevention efforts applied over long peri-
ods [10-13]. However, there has been relatively little
research, other than pilot studies, on the effects of syr-
inge exchange in developing/transitional countries. It is
therefore uncertain whether the interventions used in
developed countries will hav et h es a m ed e g r e eo fe f f e c -
tiveness in transitional countries where these interven-
tions might operate in a hostile policy environment.
Data on new injectors (i.e. people who have started to
inject drugs recently) can provide critical insights into
the dynamics of an ongoing HIV epidemic among IDUs.
First, the proportion of new injectors provides informa-
tion about the growth of the population at risk of HIV.
Second, in epidemics that are driven by injecting drug
use with little sexual transmission, all or almost all IDUs
will be HIV seronegative when they begin injecting
[14,15]. In these situations HIV prevalence among new
injectors can be used to estimate HIV incidence. Third,
new injectors are often the most difficult subgroup to
reach with HIV prevention services – possibly because
they do not identify themselves as drug injectors [16] so
that information on whether new injectors are using
HIV prevention services can be a good measure of the
reach of prevention services.
In this report, we examine trends in new injectors in
the IDU population in Tallinn, Estonia from 2005 to
2009 in relation to the expansion of harm reduction ser-
vices during the same time period.
Estonia has experienced a concentrated HIV epidemic
among IDUs, with the highest per capita HIV prevalence
in Eastern Europe. There are an estimated 10,000 IDUs
(approximately 70% of IDUs in the country) in Tallinn,
the capital and largest city [17]. Studies in Estonia have
shown a high prevalence of HIV (40-90%) [18,19], and
estimated the incidence of HIV in the IDU population
>20/100 person years at risk [20]. Based on data from
surveys conducted among IDUs in Tallinn [18,19,21], a
shift in use from heroin and home-made opiates to fen-
tanyl analogues and amphetamine has occurred during
the current decade.
Estonia’s capacity to manage its response to HIV and
AIDS has increased greatly over the past five years, parti-
cularly through funding from the Global Fund to fight
HIV/AIDS, tuberculosis, and malaria [22]. Global Fund
support was also instrumental in building capacity for the
governmental and nongovernmental sectors to interact
constructively with each other. This included establishing
systems for channeling funds through government to
NGOs and mechanisms for dialogue [23]. Amongst other
activities, reducing the risk of harm faced by IDUs by scal-
ing-up syringe exchange programs and drug treatment
were implemented. The National Institute for Health
D e v e l o p m e n t( N I H D )i sa na g e n c yo ft h eM i n i s t r yo f
Social Affairs and is responsible for implementing and
monitoring the majority of the state prevention programs
(including those targeting HIV/AIDS and drug use).
Detailed descriptions of the HIV epidemic in Estonia and
response to the epidemic can be found elsewhere [24].
SEPs were initiated in Estonia in 1997, in Tallinn. By 2009
in Tallinn, 3 organizations were providing SEP through 3
stationary centers (and 7 outreach locations) with 63,333
registered visits (1 center, 2341 visits in 2003; 2 centers,
30,863 visits in 2005) (Table 1) [25]. Methadone detoxifi-
cation has been available in Estonia since 1998, but opioid
substitution maintenance treatment with methadone was
officially introduced in 2001 [24]. By the end of 2009 in
Tallinn 3 institutions (3 centers) were providing opioid
substitution treatment (Table 1) [25].
In Estonia, during the past 10 years the number of
patients on ART has increased from 27 in 2000 to 1751
at the end of 2010 [personal communication, Mr. Mihkel
Rääk, Ministry of Social Affairs, Estonia, 24.01.2011].
However, only 5-12% of HIV-infected IDUs have
reported currently receiving ART [26].
Methods
Cross sectional studies in 2005, 2007 and 2009 were con-
ducted to assess the prevalence of HIV and risk behavior
among IDUs in Tallinn, Estonia. In each study, current
IDUs were recruited for an interviewer-administered risk
behavior survey covering demographics, drug use history,
and HIV risk behavior. HIV counseling was provided and
a blood sample was collected for HIV testing. Partici-
pants had to: be 18 years or older, be Russian or Estonian
speakers, have injected drugs in the previous two months
(one month in 2005), and be able to provide informed
consent.
Respondent driven sampling (RDS) [18,19] was used in
all three surveys. Recruitment began with the non-random
s e l e c t i o no f5-6‘seeds’ representing diverse IDU types
(by gender, ethnicity, main type of drug used, and HIV sta-
tus). Eligible participants received coupons for recruiting
up to three of their peers. Coupons were uniquely coded
to link participants to their survey responses and biological
specimens and for monitoring who recruited whom. Parti-
cipants who completed the study received a primary
incentive (a food coupon worth $ 10) for participation in
the study and a secondary incentive (a food coupon worth
$ 5 for each eligible person they recruited to the study).
The RDS technique uses participants’ social networks to
access individuals who might not appear in public venues
and might not be in contact with service providers. This
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IDUs [27,28]. A face-to-face interviewer-administered
structured questionnaire was used. In 2007 and 2009 the
questionnaire was based on the WHO Drug Injecting
Study Phase II survey (version 2b(rev.2)) [29], and in 2005,
the questionnaire was adapted from several studies in
resource-constrained and developed countries, including
the Russian Federation [30,31]. Both instruments were ori-
ginally developed to collect risk behavior data from IDUs,
and therefore contained similar measures on key behavior
characteristics (age, gender, age at injection initiation,
injection frequency, main drug injected, receptive sharing
within last 4 weeks, SEP utilization [ever, and in the last 4
weeks], number of sexual partners within last 12 months).
The instruments were modified to obtain information on
the illicit drugs known to be available in Tallinn.
Questions were selected that would elicit data on
demographics, drug use history, HIV risk behavior, HIV
testing, access and use of harm reduction services. A
question on age at first injection was included, permitting
calculation of the number of years the participant had
been injecting. Interviews were held in confidence, in a
room of the SEP. Recruitment was conducted and the
survey administrated by a team of trained fieldworkers.
Blood was collected for HIV testing. In 2005 dried
blood spot specimens were tested for HIV antibodies
using GACELISA, reactive specimens were confirmed
using an anti-HIV GACPAT immunoassay, with confir-
matory testing conducted on discordant results using the
HIV Blot 2.2 Western Blot assay (AbbotMurex) [32,33].
In 2007 and 2009, venous blood was tested with com-
mercially available kits for HIV antibodies (Abbott IMx
HIV-1/HIV-2 III Plus, Abbott Laboratories, Abbott Park,
Illinois, USA).
Several studies comparing HIV antibody testing per-
formance from serum (venous blood) and dried blood
spots have documented excellent agreement of results
between these different methods [34-36].
Data on the level of HIV prevention services provided
were obtained from the Estonian National Institute for
Health Development.
Statistical analysis
HIV incidence can be estimated from cross-sectional
data using prevalence data [37] stratified by time at risk
(years of injecting) and assuming that HIV prevalence
differences between the years of IDU duration strata
represent incident HIV infections [10,20]. The question-
naires included questions on current age and age at first
drug injection. Subtraction of age at first injection from
current age provided a measure of the number of years
injecting.
We estimated HIV incidence among new injectors
using the following assumptions: (1) all of them were
HIV seronegative when they began injecting; (2) the HIV
seropositives became infected at the midpoint between
beginning to inject and the time of blood sample collec-
tion, and (3) no HIV seropositives were lost to AIDS or
for other reasons among the new injectors. We limited
our analysis to “new injectors” (defined as a person
reporting his/her first injection as occurring within three
years of the study interview). For calculating time since
first injection, we assigned persons who had first injected
at their current age to have been injecting for 6 months,
persons who first injected in the previous year to have
been injecting for 1 year, persons who had first injected
two years prior to their current age to have been injecting
for 2 years, and persons who had first injected three years
prior to their current age to have been injecting for 3
years. The time at risk for HIV seronegative new injectors
is the total time from first injection to the time of the
interview. The estimated HIV incidence rate was the
number of HIV seropositive new injectors divided by the
sum of the time at risk for the HIV seropositive new
injectors (half the total time from beginning to inject to
t h et i m eo fi n t e r v i e w )a n dt h et i m ea tr i s kf o rt h eH I V
seronegative new injectors (total time from beginning to
inject to time of interview).
Study participation in all three studies was anon-
ymous. To control for potential duplication in the sam-
ples (2005, 2007, 2009) a combination of biometric
measures of each respondent (width of each wrist and
length of each forearm from elbow to middle finger)
and selected personal characteristics (sex, ethnicity, age)
was used. Using this method, we identified one person
who possibly participated in years 2005 and 2007. This
person was retained for the analysis in both years, given
the need for sufficiently large samples of new injectors,
and that the HIV status, time at risk, use of syringe
exchange, etc for that subject interviewed in 2005 would
have reflected conditions in 2005, while if the same sub-
ject were interviewed in 2007, the subject’sc h a r a c t e r i s -
tics would primarily reflect conditions in 2006 in
addition to reflecting conditions in 2007.
Table 1 Volume of harm reduction services provided in 2003 to 2009 in Tallinn, Estonia
Year 2003 2004 2005 2006 2007 2008 2009
No of syringes distributed 18,010 129,093 230,409 443,961 600,021 734,954 774,782
No of condoms distributed throughout SEPs 16,427 76,004 83,975 134,837 158,164 156,735 131,162
No of positions for methadone treatment 46 103 183 200 191 209
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were compared in 2005, 2007, and 2009. Pearson’s c
2,
c
2 test for trend and Fisher’se x a c tt e s t sw e r eu s e df o r
categorical variables. A multivariate analysis (controlling
for age, sex, frequency of drug and SEP use) was used
to test for trends in HIV prevalence [38].
RDS analysis Tool v. 5.0.1 was used to calculate
homophily (the extent to which recruiters are likely to
recruit individuals similar to themselves) to examine for
possible recruitment bias [39].
Ethical approval was obtained from the Ethics Review
Board of the University of Tartu, Estonia (in 2005 and
2009) and from the Tallinn Medical Research Commit-
tee (in 2007).
Results
Table 1 shows the harm reduction services provided to
IDUs in Tallinn from 2003 through 2009. The number
of methadone treatment positions ("slots”)i n c r e a s e d
from 49 to 209. With an estimated 10,000 IDUs in the
city, however, the latest number of methadone treat-
ment positions is still quite low, with methadone treat-
ment available for only approximately 2% of the IDU
population. Since 2004 the number of syringes distribu-
ted through SEPs (both stationary and outreach) in Tal-
linn has increased more than 6-fold. This corresponds
to an estimated coverage of 70 or more syringes per
IDU per year in 2008 (73.5 = 734,954/10,000) and 2009
(77.5 = 774,782/10,000).
We recruited 350 current IDUs in both 2005 and 2007
and 327 IDUs in 2009. In all three surveys, IDUs were
predominantly male (80%), ethnic Russians (>80%), and
young adults (mean ages 24 to 27 years) (full details from
individual surveys are available from the first author).
The proportion of new injectors (those injecting for less
than three years) among the IDUs decreased from 21% in
2005, to 16% in 2007, and 12% in 2009 (p <0.005 by
c
2test). Estimates for homophily indexes for the type of
IDU (new and old injectors) in all three samples were
c l o s et oz e r o ,s u g g e s t i n gas i n g l eu n d e r l y i n gp o p u l a t i o n
for each round of recruitment and non selective recruit-
ment between the two IDU groups (i.e. new and old
injectors) [27].
HIV prevalence among all subjects stabilized at slightly
over 50% (54% in 2005, 55% in 2007, 50% in 2009). There
were statistically significant differences in HIV prevalence
among new injectors, with the prevalence in 2009 less
than half that in 2007 (15.8% vs 34.2%) (Table 2). There
were, however, differences in demographic characteristics
and drug use behaviors among new injectors across the
surveys. We used multiple regression [38] to determine if
the differences in HIV prevalence remained statistically
significant after controlling for age, gender, injection fre-
quency and SEP use. The differences in HIV prevalence
among new injectors remained statistically significant
(Chi squared = 8.31, p = 0.016).
We also observed significant changes in the estimated
HIV incidence among new injectors. In 2005 and 2007,
the estimated incidences among new injectors were 20.9
per 100 person years (py), compared with 9.0/100 py in
2009 (Table 2).
During the period of the three surveys, there was an
increase in the age of IDUs both in terms of chronologi-
cal age and age of starting injecting (Table 3). Reported
injection risk behaviors (any receptive sharing in the
past 4 weeks) did not change over the three surveys.
However, the proportion of new injectors reporting hav-
ing used SEP services increased steadily throughout the
study period (from 70% in 2005 to 97% in 2009), as did
the proportion of new injectors for whom an SEP was
the current main source of syringes (from 44% in 2005
to 76% in 2009). We did not see significant changes in
reported numbers of sexual partners within the last 12
months or in condom use. There was a slight (but sta-
tistically not significant, p = 0.08) increase in the pro-
portion of new IDUs who reported not always using
condoms (37% in 2005, 58% in 2009).
Discussion
We have used a series of cross sectional studies conducted
among IDUs over a period in which harm reduction ser-
vices (mainly SEPs) were introduced and then expanded
to examine the possible effects of such programs in an
Eastern European country.
Several findings from our study are potentially impor-
tant. The proportion of new injectors among IDUs across
the surveys decreased; this suggests a decreasing rate of
individuals becoming IDUs. Drug use patterns are not
static, for example Estonia and several other Eastern
European countries witnessed explosive IDU epidemics in
the late 1990s. Limited data on the course of IDU epi-
demics after their emergence is available. In Russia, 47% of
IDUs recruited in 2003 from Moscow, Volgograd and
Barnaul [40] and 42% of IDUs recruited from St Peters-
burg in 2005-2006 [41] were new injectors (reporting
injecting for <5 years). In Russia, 47% of IDUs recruited in
2003 from Moscow, Volgograd and Barnaul [40] and 42%
of IDUs recruited from St Petersburg in 2005-2006 [41]
reported injecting for <5 years. These findings are very
similar to the 41% of IDUs recruited in Tallinn in our
2005 survey who reported injecting for <5 years. (In our
2005 survey 21% of subjects reported injecting for < = 3
years, see Table 2.) In Estonia, the decrease in numbers of
new injectors occurred at the same time as the increase in
SEP services. This contradicts the idea that providing SEP
will lead to an increase in people beginning to inject
drugs. Our sampling methods (RDS) did not change over
the three surveys and no substantial changes of drug
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years) among surveys of IDUs in Tallinn, Estonia in 2005, 2007 and 2009
The proportion of new injectors * HIV prevalence ** HIV incidence per 100 PY ***
Year New All % HIV+ % 95% CI 95% CI
2005 73 350 20,9% 25 34,2% 22.2-50.6% 20,9 13.5-30.8
2007 57 350 16,3% 22 38,6% 24.2-58.4% 26,5 16.6-40.1
2009 38 327 11,6% 6 15,8% 5.8-34.4% 9,0 3.3-19.6
* for changes of the period p = 0.005 (Chi-squared Test); ** for changes of the period p = 0.046 (Fisher Exact test); *** for changes of the period p = 0.026
(Chi-squared Test)
Table 3 Socio-demographic and behavioural (risk) characteristics among new drug injectors in 2005, 2007, and 2009,
in Tallinn, Estonia

















< = 20 45 62% 23 40% 16 42%
>20 28 38% 34 60% 22 58% 0.030 0.023
Gender
Male 54 74% 45 79% 31 82%
Female 19 26% 12 21% 7 18% 0.623 0.338
Ethnicity
Russian+Russian speaking 57 78% 47 82% 34 89%
Estonian 16 22% 10 18% 4 11% 0.330 0.140
Environmental factors
Ever in drug treatment
No 59 81% 48 84% 33 87%
Yes 13 18% 9 16% 5 13% 0.799 0.503
Ever in prison
No 44 60% 37 65% 26 68%
Yes 29 40% 20 35% 12 32% 0.679 0.381
SEP use ever
No 22 30% 16 28% 1 3%
Yes 51 70% 41 72% 37 97% 0.003 0.003
SEP as the main source of syringes (last 4
weeks)
No 41 56% 34 60% 9 24%
Yes 32 44% 23 40% 29 76% 0.001 0.004
Injecting drug use
Age at IDU initiation (years)
< = 16 27 37% 7 12% 6 16%
>16 46 63% 50 88% 32 84% 0.002 0.003
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tion [25,42]. While the belief that SEP leads to more peo-
ple beginning to inject drugs has generally been
discredited [4,8], it is important to test this belief in middle
income countries, where resistance to large-scale harm
reduction remains strong.
We observed a significant decrease in the prevalence of
HIV among new injectors from 34% and 39% in 2005 and
2007 to 16% in 2009. We also observed a decrease in the
estimated HIV incidence among new injectors from up to
27/100 py in 2005 and 2007 to 9.0/100 py in 2009. The
estimated incidence among new injectors showed a non-
significant rise in 2007 (and a decline by 2009) coinciding
with the rise and decline in the proportion of new injec-
tors reporting daily injecting. While the level of HIV infec-
tion among new injectors in Estonia is still clearly
unacceptably high, the change from the preceding years is
substantial. Acknowledging that, in Estonia, active treat-
ment for addiction (i.e. opioid substitution treatment) cov-
erage and ART coverage among HIV infected IDUs [26]
were implemented at a suboptimal level [43] during this
period, preventing any meaningful public-health level
effect, it is reasonable to attribute the decrease in HIV
infection among new injectors to the greatly increased
access to clean syringes/SEPs.
Limitations
The cross-sectional design of the study sets well-known
limits for causal inference. However, repeated cross-
s e c t i o n a ls t u d i e sm a yb ec o n s i d e r e dt oc o n s t i t u t eap s e u d o -
longitudinal study, given that the IDUs recruited in the stu-
dies were sampled from the IDU source population using
the same methodology. We used a non-probability sample
that may have implications for the representativeness of
the study results. However, RDS was used for recruitment
because it is a sampling technique known to overcome
some of the limitations of convenience sampling [27,28].
Other potential sources of bias associated with the sensitive
and illegal behaviors under investigation are socially desir-
able responses and recall bias. However, we suggest that
this would be expected to influence study participants in a
similar way in different years. In addition, for HIV inci-
dence estimations we made assumptions that might not
hold. There is a possible loss of HIV seropositives from the
active new injector population, due to ceasing to inject
(perhaps because of methadone use), and to death/disabil-
ity from AIDS. To minimize those effects we estimated the
incidence only among new injectors, those who have
injected for only a short period (3 years), and who would
have been very unlikely to have developed AIDS and, given
the limited availability of methadone treatment in Tallinn,
they would also have been very unlikely to have received
methadone treatment. It is of importance to note that we
do not have data on the potential changes in IDU preva-
lence in Tallinn. However there are no declines in the
numbers of criminal offences that can be related to the
drug use or in the numbers of drug use related deaths in
the recent years (2006-2009) [42].
Table 3 Socio-demographic and behavioural (risk) characteristics among new drug injectors in 2005, 2007, and 2009,
in Tallinn, Estonia (Continued)
Frequency of injection (last 4 weeks)
Less than daily 57 78% 30 53% 27 71%
Daily 16 22% 27 47% 11 29% 0.008 0.189
Main drug injected (last 4 weeks)
Fentanyl 35 48% 33 58% 23 61%
Amphetamine 34 47% 23 40% 12 32% 0.321 0.132
Receptive sharing (last 4 weeks)
No 54 74% 47 82% 30 79%
Yes 19 26% 10 18% 8 21% 0.505 0.435
Sexual behaviors
Number of sexual partners (last 12 months)
0-1 32 44% 37 65% 15 39%
1+ 40 55% 20 35% 23 61% 0.022 0.984
Condom use (last 4 weeks)*
always 26 36% 11 19% 9 24%
else 27 37% 15 26% 22 58% 0.199 0.076
* Among those reporting vaginal or anal intercourses with in last 4 weeks
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injecting risk behavior did not capture important changes
in injecting risk. For example, it is possible that IDUs in
Tallinn reduced the frequency with which they shared
injecting equipment (which would not be captured by the
“any sharing” questions), or that they reduced the numbers
of persons with whom they shared, or that some form of
serosorting occurred, in which HIV seronegatives were
more likely to share with other seronegatives and HIV ser-
opositives were more likely to share with other seroposi-
tives. The numbers of syringes provided to IDUs may be a
better measure of transmission probability than questions
on “any sharing” during a short time period.
IDUs in Tallinn also obtain sterile injection equipment
from pharmacies [28] and we were not able to determine
the numbers of syringes obtained from pharmacies over
the 2005 to 2009 time period. Despite some imprecision
in determining the numbers of sterle needles and syr-
inges obtained by IDUs in Tallinn over the time period
covered by the surveys, it is clear from the data in Table
1 that there was a very substantial incorease in the provi-
sion of sterile injecting equipment. The coverage of 70
syringes per IDU per year reached by 2009 corresponds
to the low coverage indicator set by the WHO, UNODC,
UNAIDS for universal access to HIV prevention, treat-
ment and care for injecting drug users [43], based on stu-
dies in the UK and Belarus [44] and the USA [45].
Conclusions
Allocating resources for the prevention of HIV infection
among IDUs is a challenging task. A large-scale SEP
appears to have been quite effective in Estonia (a transi-
tional country), although further reductions in HIV
transmission among IDUs are still required. Coverage of
70 or more syringes per IDU per year may be needed
before significant reductions in HIV incidence occur.
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